Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.

ABSTRACT:

Aims

To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups.

Methods

In a nationwide, population-based cohort study, we identified all individuals treated with sotrovimab (N = 2933) and stratified them by 4 high-risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti-CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors.

Results

Of 2933 sotrovimab-treated individuals, 83% belonged to high-risk groups (37.6% haematological malignancy, 27.4% solid organ transplantation and 17.5% treatment with anti-CD20 ≤1 year). Only 17.8% had othe

SUBMITTER: Rasmussen LD 

PROVIDER: S-EPMC9878138 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature